<DOC>
	<DOCNO>NCT01912560</DOCNO>
	<brief_summary>The purpose study determine safety efficacy different dos CAT-2003 patient hyperlipidemia CAT-2003 take 4 week . The study evaluate effect CAT-2003 ( 1 ) fast triglycerides non-HDL-C patient moderate hypertriglyceridemia ( 2 ) fast LDL-C level combination statin patient hypercholesterolemia statin .</brief_summary>
	<brief_title>Pilot Study To Assess CAT-2003 Patients With Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Between 18 69 year Screening Hypertriglyceridemia ( TG ≥ 200 mg/dL &lt; 500 mg/dL nonHDLC ≥ 100 mg/dL &lt; 220 mg/dL ) OR Hypercholesterolemia ( LDLC ≥ 100 mg/dL &lt; 190 mg/dL TG value &lt; 200 mg/dL ) plus stable dose statin least 4 week prior Screening . Body mass index ( BMI ) ≤ 45 kg/m2 History major cardiovascular event within 6 month Screening Type I diabetes mellitus Any condition may predispose patient secondary hyperlipidemia , uncontrolled hypothyroidism Any statin high approve dose Nonstatin lipidaltering drug cholesterol absorption inhibitor . Active peptic ulcer disease history muscle disease myopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>